In Vitro Detection of Tissue Abnormality
Primary Purpose
Breast Cancer Female
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Testing a new device (LS BioPath TOUCH) on excised tissue
Sponsored by
About this trial
This is an interventional treatment trial for Breast Cancer Female
Eligibility Criteria
Inclusion Criteria:
- Patients aged 25-80 who are scheduled for surgical excision of tissue.
Exclusion Criteria:
- No prior history of surgery at location of current surgery.
Sites / Locations
- St. Mary's
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Device image reading
Arm Description
Tissue images generated by the device are read by surgeons to determine if the tissue area under test has abnormal component or not. When Images generated by the device are read by surgeons as abnormal an additional margin of tissue is removed. The new margin is also imaged by the device to ensure complete tumor excision.
Outcomes
Primary Outcome Measures
•Accuracy of LS BioPath TOUCH device compared to pathology
Assess percentage of FP and FN of test device results compared to pathology results
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01209182
Brief Title
In Vitro Detection of Tissue Abnormality
Official Title
In Vitro Detection of Tissue Abnormality
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
October 15, 2010 (Actual)
Primary Completion Date
December 13, 2011 (Actual)
Study Completion Date
January 9, 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
LS BioPath
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
Intraoperative ex-vivo use of the ClearEdge Imaging Device in Breast Conserving Surgery to image the excised tissue surgical margins. The study is designed to demonstrate reduction in the need for repeat surgeries after breast conserving surgeries by using the ClearEdge as an adjunct imaging device to the standard of care.
Detailed Description
Intraoperative real-time margin assessment of breast conserving surgeries can reduce the need for repeat operations due to cancer involved margins. Repeat operations result in excessive removal of benign tissue, increased risk for infection, slower healing and inferior cosmetic results. In the current standard of care, the status of the margins is determined by pathology only several days after surgery. An intraoperative assessment of the margins enables complete tumor excision in a single surgery.
The proposed randomized controlled study will evaluate the benefits of adding the ClearEdge imaging device to the Standard of Care (SoC) of margins assessment in breast conserving surgeries. The study will assess whether there is an improvement in the detection of cancer involved margins by measuring whether removal at the time of primary surgical treatment can reduce the need for repeat surgeries as compared to the SoC, which does not use the device.
ClearEdge is a CE marked device already been used in several hospitals in the UK. It was used in a prospective single arm and 2 phases clinical study. It was demonstrated that surgeons successfully used the device to identify cancer involved margins and that it can reduce the need for repeat surgeries by meeting the margins depth criteria to require repeat operations. European Journal of Oncology Surgery. 2016; 42 (12): 1834-1840. In addition, the device was clinically evaluated by several hospitals.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer Female
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
2 phase study: Phase 1 - Validation of safety and accuracy when used ex-vivo to image excised breast surgery specimens Phase 2 - To guide surgeon's decision to re-excise additional margins during primary operation
Masking
None (Open Label)
Allocation
N/A
Enrollment
121 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Device image reading
Arm Type
Experimental
Arm Description
Tissue images generated by the device are read by surgeons to determine if the tissue area under test has abnormal component or not. When Images generated by the device are read by surgeons as abnormal an additional margin of tissue is removed. The new margin is also imaged by the device to ensure complete tumor excision.
Intervention Type
Device
Intervention Name(s)
Testing a new device (LS BioPath TOUCH) on excised tissue
Intervention Description
Measurements are obtained with test device on excised tissue.
Primary Outcome Measure Information:
Title
•Accuracy of LS BioPath TOUCH device compared to pathology
Description
Assess percentage of FP and FN of test device results compared to pathology results
Time Frame
1 week after surgery
10. Eligibility
Sex
Female
Gender Based
Yes
Gender Eligibility Description
biologic females
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients aged 25-80 who are scheduled for surgical excision of tissue.
Exclusion Criteria:
No prior history of surgery at location of current surgery.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Lagios, MD
Organizational Affiliation
St. Mary's Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Mary's
City
San Francisco
State/Province
California
ZIP/Postal Code
94117
Country
United States
12. IPD Sharing Statement
Learn more about this trial
In Vitro Detection of Tissue Abnormality
We'll reach out to this number within 24 hrs